Meningococcal C conjugate vaccine: the experience in England and Wales.
Meningococcal C conjugate vaccine was introduced in the UK in November 1999 together with a comprehensive meningococcal surveillance strategy to support and inform the vaccine programme. These surveillance data have provided important information on the long-term effectiveness of the programme, through direct and indirect protection, and on the prevalent serotypes and serosubtypes causing invasive meningococcal infection subsequent to vaccine introduction. The MCC immunization programme has been extremely successful in controlling serogroup C disease and continues to be evaluated. The aim of this paper is to review the experiences in England and Wales over the past 9 years.
Campbell
Helen
H
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK. helen.campbell@hpa.org.uk
Borrow
Ray
R
Salisbury
David
D
Miller
Elizabeth
E
D004739:England / Q000453:epidemiology; D006801:Humans; D008585:Meningitis, Meningococcal / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology*; D038542:Neisseria meningitidis, Serogroup C / Q000302:isolation & purification*; D011159:Population Surveillance / Q000379:methods; D014852:Wales / Q000453:epidemiology
D022401:Meningococcal Vaccines; C410218:serogroup C meningococcal conjugate vaccine